Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Review ArticlePractice

Familial hypercholesterolemia

Review of diagnosis, screening, and treatment

Ricky D. Turgeon, Arden R. Barry and Glen J. Pearson
Canadian Family Physician January 2016, 62 (1) 32-37;
Ricky D. Turgeon
Clinical pharmacist at Vancouver General Hospital in British Columbia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arden R. Barry
Assistant Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of British Columbia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glen J. Pearson
Professor of Medicine in the Division of Cardiology in the Faculty of Medicine at the University of Alberta in Edmonton.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Glen.Pearson@ualberta.ca
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Objective To summarize the pathophysiology, epidemiology, screening, diagnosis, and treatment of familial hypercholesterolemia (FH).

Quality of evidence A PubMed search was conducted (inception to July 2014) for articles on pathophysiology, screening, diagnosis, and management of FH, supplemented with hand searches of bibliographies of guidelines and reviews. A supporting level of evidence for each recommendation was categorized as level I (randomized controlled trial or systematic review of randomized controlled trials), level II (observational study), or level III (expert opinion). The best available evidence is mostly level II or III.

Main message Familial hypercholesterolemia affects 1 in 500 Canadians. Risk of a coronary event is high in these patients and is underestimated by risk calculators (eg, Framingham). Clinicians should screen patients according to guidelines and suspect FH in any patient with a premature cardiovascular event, physical stigmata of hypercholesterolemia, or an elevated plasma lipid level. Physicians should diagnose FH using either the Simon Broome or Dutch Lipid Network criteria. Management of heterozygous FH includes reducing low-density lipoprotein levels by 50% or more from baseline with high-dose statins and other lipid-lowering agents. Clinicians should refer any patient with homozygous FH to a specialized centre.

Conclusion Familial hypercholesterolemia represents an important cause of premature cardiovascular disease in Canadians. Early identification and aggressive treatment of individuals with FH reduces cardiovascular morbidity and mortality.

Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that produces elevations in low-density lipoprotein (LDL) cholesterol.1 High levels of circulating LDL lead to the rapid development of atherosclerosis early in life, which results in the premature development of atherosclerotic cardiovascular disease (ASCVD). In practice, clinicians underrecognize FH and frequently only make the diagnosis once patients present with an ASCVD event at a young age.1,2 Patients with FH require aggressive treatment, often with multiple pharmacologic agents, to reduce their levels of circulating LDL cholesterol in order to curtail ASCVD risk. In this review, we aim to summarize the pathophysiology, epidemiology, screening, diagnosis, and treatment of FH.

Quality of evidence

We conducted a PubMed search (inception to July 2014), supplemented with hand searches of bibliographies of clinical practice guidelines, position papers, and reviews. Recommendations from Canadian authorities, when available, were prioritized. Recommendations were rated from levels I to III: level I evidence included 1 or more properly conducted randomized controlled trials (RCTs) or systematic reviews of RCTs with or without meta-analysis; level II evidence included 1 or more controlled observational studies (cohort, case-control, or other relevant epidemiologic studies); and level III evidence included all opinion-based statements with no empiric supporting evidence.

Main message

Pathophysiology and epidemiology. Genetic mutations cause FH.3 Defects in the genes that code for the LDL receptor, apolipoprotein B, or proprotein convertase subtilisin-kexin type 9 (PCSK9) ultimately lead to impaired clearance of LDL cholesterol from the plasma. Low-density lipoprotein receptors, found primarily on hepatocyte cell membranes, are responsible for uptake of LDL particles and thus removal of cholesterol from plasma. Apolipoprotein B is the LDL-bound protein that binds to the LDL receptor. Finally, PCSK9 is responsible for the degradation of LDL receptors; thus, genetic defects leading to elevated PCSK9 levels will result in decreased LDL receptors on hepatocytes, and thus hyperlipidemia. A single copy of the defective gene (heterozygous) leads to moderate accumulation of plasma LDL, whereas 2 copies of the same defective gene (homozygous) or 2 coexisting mutations (compound heterozygous) lead to extensive accumulation due to minimal or no LDL cholesterol clearance. Clinically, patients with heterozygous FH (HeFH) typically have an LDL plasma concentration of 5 to 13 mmol/L, whereas patients with homozygous FH (HoFH) have an LDL level well above 13 mmol/L.4

Approximately 1 in 500 Canadians has HeFH. Prevalence of FH varies based on ethnic background, with higher rates among Québécois French Canadians (1 in 270), Lebanese (1 in 85), Afrikaners (1 in 72), and Ashkenazi Jews (1 in 67).5 Homozygous FH, the more severe form, affects approximately 1 out of every 1 million individuals.5

Complications and prognosis. Without early and aggressive treatment, FH manifests as premature ASCVD events, often affecting the coronary arteries. Patients with untreated HeFH tend to experience a first coronary event 20 or more years earlier than the general population (mean age 42 vs 64).6 Consequently, their cumulative risk of a coronary event by age 50 is up to 44% in men and 20% in women.6,7 This cardiovascular risk is far greater than that predicted by cardiovascular risk calculators (eg, Framingham risk score), and therefore these calculators should not be used in patients with FH.8 Untreated HoFH is associated with an even worse prognosis, with many patients experiencing coronary events in childhood or adolescence.9,10

Lipid screening. Table 1 provides a summary of the recommendations on screening for FH. The Canadian Cardiovascular Society (CCS) dyslipidemia guidelines and FH position statement recommend universal screening of plasma lipids in all men 40 years of age or older and all women 50 years of age or older or after menopause.1,8 Furthermore, they recommend screening individuals with conditions that increase their risk of cardiovascular disease (eg, those who have hypertension, diabetes mellitus, chronic kidney disease, or who are current smokers) regardless of age.

View this table:
  • View inline
  • View popup
Table 1.

Summary of recommendations

For pediatric screening, guidelines released by the National Heart Lung and Blood Institute recommend routine universal screening of plasma lipids at 11 years of age, or as early as 12 months in children with a first-degree family history of ASCVD or FH.11 As atherosclerosis begins early in life for individuals with FH (especially in HoFH), childhood screening is intended to facilitate early identification and treatment. Despite the theoretical benefits of the National Heart Lung and Blood Institute screening program, there are complex logistical challenges in implementation, as well as limited data for the optimal time to initiate treatment, which have stimulated controversy.12

Once a proband (or index case) of FH has been identified, the CCS position statement on FH recommends further “cascade screening.”1 This involves the screening of first-degree relatives of individuals with confirmed FH to identify undiagnosed cases. If a relative is found to have FH, their relatives should also be screened, and so forth. This strategy is based on the autosomal dominant inheritance pattern of FH. Individuals who are first-, second-, and third-degree relatives of an individual with HeFH will have a 50%, 25%, and 12.5% likelihood, respectively, of also having FH. On average, cascade screening identifies 8 new cases of FH for every proband.13 A number of countries have initiated different variations of cascade screening, which have demonstrated favourable cost-effectiveness.14 Patients can be enrolled into the Canadian FH registry through referral to a participating clinician or centre. Information can be obtained from the FH Canada website (www.fhcanada.net/fh-canada-registry).

Diagnosis. In practice, clinicians frequently miss FH. Of the estimated 83 500 individuals with FH in Canada, only approximately 5% have received an appropriate diagnosis.1,2 Clinicians should suspect FH in any patient with a premature cardiovascular event, physical stigmata of hypercholesterolemia (ie, arcus senilis, xanthoma, or tendinous xanthoma) or a plasma LDL level of 5 mmol/L or higher.15

Once hypercholesterolemia is identified, physicians should rule out secondary causes, such as medical conditions (eg, hypothyroidism, diabetes mellitus, nephrotic syndrome, obstructive liver disease), drugs (eg, corticosteroids, diuretics), excess alcohol consumption, very poor diet, and a sedentary lifestyle (Table 1).

The CCS position statement on FH recommends making the diagnosis of FH using 1 of 2 score-based diagnostic criteria: the Simon Broome Register or the Dutch Lipid Network criteria (Table 2).1,16 Both sets of diagnostic criteria perform reasonably well with no clear criterion standard.17 The diagnosis of FH does not require genetic testing, as approximately 1 in 5 patients with a clinical diagnosis of HeFH have negative test results for all currently known genetic mutations.

View this table:
  • View inline
  • View popup
Table 2.

Diagnostic criteria of FH

Treatment. Despite the high ASCVD risk associated with FH, as many as 50% of patients with a proper diagnosis fail to receive adequately aggressive treatment, possibly owing to an underappreciation of the magnitude of the risk.18,19 The primary goal for the treatment of FH is to reduce mortality and ASCVD events, which is achieved by reducing plasma LDL levels.1,20,21

Although there is no evidence to support any specific LDL target in this population, guidelines generally recommend a reduction of 50% or more from baseline,1,20,21 similar to recommendations for the general population.8 Dietary modifications are important to lower LDL levels; however, it is not possible for most FH patients to achieve their lipid level targets without additional interventions.22 Management of traditional ASCVD risk factors, such as cessation of tobacco use and treatment of hypertension and diabetes, are crucial in FH patients owing to their high baseline ASCVD risk.23

In terms of the pharmacotherapeutic management of HeFH, high-dose statins are first-line therapy. In an RCT of patients with HeFH, treatment with 80 mg of atorvastatin daily reduced LDL levels by an average of 50% from baseline,24 similar to results obtained in the population without FH.25 Beyond LDL reduction, evidence supporting a reduction in clinically relevant outcomes with statin therapy (or any lipid-lowering therapy) in HeFH is primarily observational. One cohort study demonstrated that a moderate dose of statin therapy (eg, 40 mg of atorvastatin daily) reduced the 10-year risk of coronary heart disease from 60% to 10% (adjusted hazard ratio 0.18, 95% CI 0.13 to 0.25).19 Furthermore, patients with HeFH taking statin therapy had an ASCVD risk that was only slightly higher than an age-matched sample of the general population (6.7 vs 4.1 events per 1000 patient-years). Other studies show similar improvements in prognosis with statin treatment.26,27

In patients who fail to achieve a 50% or greater reduction in LDL levels with maximally tolerated statin therapy, the CCS position statement on FH recommends adding other LDL-lowering agents.1 Ezetimibe lowers LDL levels by an additional 15% to 20% and generally has few adverse effects when combined with statin therapy.28,29 The Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (known as the ENHANCE trial), which enrolled patients with HeFH, had insufficient power to detect changes in clinically relevant outcomes.28 The largest ezetimibe RCT, IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), evaluated the use of ezetimibe in addition to 40 mg of simvastatin daily in 18 144 postacute coronary syndrome patients with LDL levels of 1.3 to 3.2 mmol/L.29 In this secondary prevention population without FH, the addition of ezetimibe to statin therapy reduced the absolute risk of cardiovascular events— primarily nonfatal myocardial infarction or stroke—by 2% over the course of 7 years, with no increased risk of adverse events. The strong pathologic role of LDL levels in the development of ASCVD in FH would predict similar relative benefit in this population.

Additional options include bile-acid sequestrants (eg, cholestyramine, colesevelam), fibrates, or niacin.20 Bile-acid sequestrants and niacin are often poorly tolerated owing to gastrointestinal adverse effects and skin flushing, respectively. Clinicians must use caution when combining a fibrate or niacin with statin therapy owing to the increased risk of myopathies.30,31 Finally, PCSK9 inhibitors such as evolocumab might provide additional options to further lower LDL levels in the future, pending Health Canada approval. Table 332–38 summarizes the new lipid-lowering agents for the treatment of HoFH.

View this table:
  • View inline
  • View popup
Table 3.

Summary of new lipid-lowering agents for the treatment of HoFH

Limited data exist for the treatment of HeFH in children. Randomized controlled trials of lipid-lowering agents in pediatric patients have thus far demonstrated an LDL reduction consistent with that seen in adults but, owing to limited enrollment and follow-up, have not demonstrated an effect on clinical outcomes.39–41 In general, the management of pediatric patients with HeFH is similar to treatment of adults.

The management of HoFH requires specialist care with aggressive pharmacologic lipid-lowering treatment, as well as lipoprotein apheresis in select patients.1 Lipoprotein apheresis is an expensive procedure that involves extracorporeal filtering of lipoproteins from blood, generally performed over a few hours on a weekly or twice-monthly basis. As with HeFH, statins and ezetimibe are first- and second-line therapy, with bile-acid sequestrants, fibrates, and niacin used less frequently. Two new agents, lomitapide and mipomersen (Table 3),32–38 show promise in the treatment of HoFH. In 2014, Health Canada approved lomitapide for use in HoFH, whereas mipomersen is not yet commercially available in Canada. There might also be a future role for PCSK9 inhibitors in the treatment of HoFH patients.

Conclusion

Familial hypercholesterolemia is an underrecognized and undertreated cause of cardiovascular disease. Clinicians should screen patients for FH and diagnose it according to CCS recommendations. Core management of HeFH relies on aggressive pharmacologic lipid lowering and ASCVD risk factor management. Clinicians should refer all patients with HoFH to a specialized centre for aggressive lipid lowering. New and upcoming pharmacologic agents offer additional options for lipid lowering.

Notes

EDITOR’S KEY POINTS

  • Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that produces elevations in low-density lipoprotein (LDL) cholesterol. It is an underrecognized and undertreated cause of cardiovascular disease.

  • The primary goal for the treatment of FH is to reduce mortality and atherosclerotic cardiovascular disease events, which is achieved by reducing plasma LDL levels. Although there is no evidence to support any specific LDL target in this population, guidelines generally recommend a reduction of 50% or more from baseline. Dietary modifications are important to lower LDL levels; however, additional interventions are required to achieve target lipid levels.

  • Patients with FH require aggressive treatment, often with multiple pharmacologic agents, as well as atherosclerotic cardiovascular disease risk factor management (eg, tobacco use, hypertension).

Footnotes

  • This article is eligible for Mainpro-M1 credits. To earn credits, go to www.cfp.ca and click on the Mainpro link.

  • This article has been peer reviewed.

  • La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro de janvier 2016 à la page e4.

  • Contributors

    All authors contributed to the literature review, analysis, and interpretation, and to preparing the manuscript for submission.

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Genest J,
    2. Hegele RA,
    3. Bergeron J,
    4. Brophy J,
    5. Carpentier A,
    6. Couture P,
    7. et al
    . Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol 2014;30(12):1471-81. Epub 2014 Oct 2.
    OpenUrlPubMed
  2. 2.↵
    1. World Health Organization
    . Familial hypercholesterolaemia (FH). Report of a second WHO consultation. Geneva, Switz: World Health Organization; 1999. Available from: http://apps.who.int/iris/bitstream/10665/66346/1/WHO_HGN_FH_CONS_99.2.pdf. Accessed 2015 Nov 23.
  3. 3.↵
    1. Faiz F,
    2. Hooper AJ,
    3. van Bockxmeer FM
    . Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins. Crit Rev Clin Lab Sci 2012;49(1):1-17. Epub 2012 Jan 4.
    OpenUrlPubMed
  4. 4.↵
    1. Cuchel M,
    2. Bruckert E,
    3. Ginsberg HN,
    4. Raal FJ,
    5. Santos RD,
    6. Hegele RA,
    7. et al
    . Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014;35(32):2146-57. Epub 2014 Jul 22.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Austin MA,
    2. Hutter CM,
    3. Zimmern RL,
    4. Humphries SE
    . Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004;160(5):407-20.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Stone NJ,
    2. Levy RI,
    3. Fredrickson DS,
    4. Verter J
    . Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974;49(3):476-88.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Hu M,
    2. Lan W,
    3. Lam CW,
    4. Mak YT,
    5. Pang CP,
    6. Tomlinson B
    . Heterozygous familial hypercholesterolemia in Hong Kong Chinese. Study of 252 cases. Int J Cardiol 2013;167(3):762-7. Epub 2012 Mar 30.
    OpenUrlPubMed
  8. 8.↵
    1. Anderson TJ,
    2. Gregoire J,
    3. Hegele RA,
    4. Couture P,
    5. Mancini GB,
    6. McPherson R,
    7. et al
    . 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29(2):151-67.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Raal FJ,
    2. Pilcher GJ,
    3. Panz VR,
    4. van Deventer HE,
    5. Brice BC,
    6. Blom DJ,
    7. et al
    . Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011;124(20):2202-7. Epub 2011 Oct 10.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Macchiaiolo M,
    2. Gagliardi MG,
    3. Toscano A,
    4. Guccione P,
    5. Bartuli A
    . Homozygous familial hypercholesterolaemia. Lancet 2012;379(9823):1330. Epub 2012 Jan 27.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute
    . Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. Pediatrics 2011;128(Suppl 5):S213-56. Epub 2011 Nov 14.
    OpenUrlFREE Full Text
  12. 12.↵
    1. Newman TB,
    2. Pletcher MJ,
    3. Hulley SB
    . Overly aggressive new guidelines for lipid screening in children: evidence of a broken process. Pediatrics 2012;130(2):349-52. Epub 2012 Jul 23.
    OpenUrlFREE Full Text
  13. 13.↵
    1. Umans-Eckenhausen MA,
    2. Defesche JC,
    3. Sijbrands EJ,
    4. Scheerder RL,
    5. Kastelein JJ
    . Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357(9251):165-8.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Ademi Z,
    2. Watts GF,
    3. Juniper A,
    4. Liew D
    . A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol 2013;167(6):2391-6. Epub 2013 Mar 13.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Hopkins PN,
    2. Toth PP,
    3. Ballantyne CM,
    4. Rader DJ
    . Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5(Suppl 3):S9-17. Epub 2011 Apr 3.
    OpenUrlPubMed
  16. 16.↵
    1. Varghese MJ
    . Familial hypercholesterolemia: a review. Ann Pediatr Cardiol 2014;7(2):107-17.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Civeira F,
    2. Ros E,
    3. Jarauta E,
    4. Plana N,
    5. Zambon D,
    6. Puzo J,
    7. et al
    . Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008;102(9):1187-93, 1193.e1. Epub 2008 Aug 27.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Benn M,
    2. Watts GF,
    3. Tybjaerg-Hansen A,
    4. Nordestgaard BG
    . Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012;97(11):3956-64. Epub 2012 Aug 14.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Versmissen J,
    2. Oosterveer DM,
    3. Yazdanpanah M,
    4. Defesche JC,
    5. Basart DC,
    6. Liem AH,
    7. et al
    . Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. National Institute for Health and Clinical Excellence, The National Collaborating Centre for Primary Care
    . Identification and management of familial hypercholesterolaemia. NICE clinical guidelines, no. 71. London, UK: Royal College of General Practitioners; 2008.
  21. 21.↵
    1. Watts GF,
    2. Gidding S,
    3. Wierzbicki AS,
    4. Toth PP,
    5. Alonso R,
    6. Brown WV,
    7. et al
    . Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014;171(3):309-25. Epub 2013 Nov 20.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Malhotra A,
    2. Shafiq N,
    3. Arora A,
    4. Singh M,
    5. Kumar R,
    6. Malhotra S
    . Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst Rev 2014;(6):CD001918.
  23. 23.↵
    1. Jansen AC,
    2. van Aalst-Cohen ES,
    3. Tanck MW,
    4. Trip MD,
    5. Lansberg PJ,
    6. Liem AH,
    7. et al
    . The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004;256(6):482-90.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Smilde TJ,
    2. van Wissen S,
    3. Wollersheim H,
    4. Trip MD,
    5. Kastelein JJ,
    6. Stalenhoef AF
    . Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357(9256):577-81.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. LaRosa JC,
    2. Grundy SM,
    3. Waters DD,
    4. Shear C,
    5. Barter P,
    6. Fruchart JC,
    7. et al
    . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35. Epub 2005 Mar 8.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Scientific Steering Committee on behalf of the Simon Broome Register Group
    . Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142(1):105-12.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Harada-Shiba M,
    2. Sugisawa T,
    3. Makino H,
    4. Abe M,
    5. Tsushima M,
    6. Yoshimasa Y,
    7. et al
    . Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2010;17(7):667-74. Epub 2010 Jun 4.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Kastelein JJ,
    2. Akdim F,
    3. Stroes ES,
    4. Zwinderman AH,
    5. Bots ML,
    6. Stalenhoef AF,
    7. et al
    . Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358(14):1431-43. Epub 2008 Mar 30.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Cannon CP,
    2. Blazing MA,
    3. Giugliano RP,
    4. McCagg A,
    5. White JA,
    6. Theroux P,
    7. et al
    . Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372(25):2387-97. Epub 2015 Jun 3.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Amend KL,
    2. Landon J,
    3. Thyagarajan V,
    4. Niemcryk S,
    5. McAfee A
    . Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother 2011;45(10):1230-9. Epub 2011 Sep 13.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Landray MJ,
    2. Haynes R,
    3. Hopewell JC,
    4. Parish S,
    5. Aung T,
    6. Tomson J,
    7. et al
    . Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371(3):203-12.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Rader DJ,
    2. Kastelein JJ
    . Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 2014;129(9):1022-32.
    OpenUrlFREE Full Text
  33. 33.
    1. Aegerion Pharmaceuticals
    . Juxtapid [product monograph]. Toronto, ON: Aegerion Pharmaceuticals; 2014. Available from: www.aegerion.ca/collateral/documents/Canada-English/FINAL%20Pristine%20Monograph%20copy.pdf. Accessed 2015 Nov 23.
  34. 34.
    1. Cuchel M,
    2. Meagher EA,
    3. du Toit Theron H,
    4. Blom DJ,
    5. Marais AD,
    6. Hegele RA,
    7. et al
    . Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381(9860):40-6. Epub 2012 Nov 2.
    OpenUrlCrossRefPubMed
  35. 35.
    1. Genzyme [website]
    . Kynamaro. Highlights of prescribing information. Cambridge, MA: Genzyme; 2013. Available from: www.genzyme.com/Products/~/media/B866EE59A7C14916BFBFB4ECAA1C7087.pdf. Accessed 2015 Nov 23.
  36. 36.
    1. Raal FJ,
    2. Santos RD,
    3. Blom DJ,
    4. Marais AD,
    5. Charng MJ,
    6. Cromwell WC,
    7. et al
    . Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9719):998-1006.
    OpenUrlCrossRefPubMed
  37. 37.
    1. Akdim F,
    2. Visser ME,
    3. Tribble DL,
    4. Baker BF,
    5. Stroes ES,
    6. Yu R,
    7. et al
    . Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010;105(10):1413-9. Epub 2010 Mar 30.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Navarese EP,
    2. Kolodziejczak M,
    3. Schulze V,
    4. Gurbel PA,
    5. Tantry U,
    6. Lin Y,
    7. et al
    . Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015;163(1):40-51.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Vuorio A,
    2. Kuoppala J,
    3. Kovanen PT,
    4. Humphries SE,
    5. Strandberg T,
    6. Tonstad S,
    7. et al
    . Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2010;(7):CD006401.
  40. 40.
    1. Avis HJ,
    2. Hutten BA,
    3. Gagne C,
    4. Langslet G,
    5. McCrindle BW,
    6. Wiegman A,
    7. et al
    . Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010;55(11):1121-6.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Van der Graaf A,
    2. Cuffie-Jackson C,
    3. Vissers MN,
    4. Trip MD,
    5. Gagne C,
    6. Shi G,
    7. et al
    . Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008;52(17):1421-9.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 62 (1)
Canadian Family Physician
Vol. 62, Issue 1
1 Jan 2016
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Familial hypercholesterolemia
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Familial hypercholesterolemia
Ricky D. Turgeon, Arden R. Barry, Glen J. Pearson
Canadian Family Physician Jan 2016, 62 (1) 32-37;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Familial hypercholesterolemia
Ricky D. Turgeon, Arden R. Barry, Glen J. Pearson
Canadian Family Physician Jan 2016, 62 (1) 32-37;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Quality of evidence
    • Main message
    • Conclusion
    • Notes
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • Hypercholestérolémie familiale
  • PubMed
  • Google Scholar

Cited By...

  • Case of homozygous familial hypercholesterolaemia with premature coronary artery disease
  • Familial hypercholesterolemia: Detect, treat, and ask about family
  • American Association of Clinical Endocrinologists/American College of Endocrinology Management of Dyslipidemia and Prevention of Cardiovascular Disease Clinical Practice Guidelines
  • Medication therapy disease management: Geisingers approach to population health management
  • Google Scholar

More in this TOC Section

Practice

  • Is 45 the new 50 in colorectal cancer screening?
  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
  • Determining if and how older patients can safely stay at home with additional services
Show more Practice

Clinical Review

  • Parkinson disease primer, part 2: management of motor and nonmotor symptoms
  • Parkinson disease primer, part 1: diagnosis
  • Prescribing for common complications of spinal cord injury
Show more Clinical Review

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire